HealthTree Myeloma Clinical Trials Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Clinical Trial

Recruiting

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

          Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Est. Enrollment: 65 participants

Study Start Date: Nov 18, 2019

Study Completion Date: Nov 01, 2035

Age: 18+ years

Gender: All

Who can join

Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
Documented measurable disease
Adequate organ function
Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

Who cannot join

Plasma Cell Leukemia or History of Plasma Cell Leukemia
Patients with a history of severe hypersensitivity to DMSO should be excluded
Contraindication to fludarabine or cyclophosphamide
Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
Active central nervous system disease involvement by malignancy or active CNS pathology

Study Description

Study Details